PDS Biotechnology adds three industry veterans to its board to accelerate the development of PDS0301 for metastatic colorectal cancer and drive potential partnerships for its PDS0101 immunotherapy platform.
PDS Biotechnology announced the appointment of three experienced pharma executives to its board, a neutral corporate governance event with potential positive implications for pipeline advancement.
PDS Biotechnology has expanded its board of directors with the appointment of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel. The new members bring extensive expertise in corporate development, commercialization, and regulatory affairs to support the advancement of the company's lead clinical candidates.
The appointments are intended to leverage the new members' expertise in corporate development and regulatory affairs to advance the company's clinical pipeline, specifically PDS0301 and PDS0101.